Please provide your email address to receive an email when new articles are posted on . Depemokimab has high binding affinity and potency for IL-5. Eosinophils fell by 83% and 82% with treatment in ...

Verekitug, 100 mg dosed every 12 weeks, reduced AAER by 56% compared to placebo in patients with severe asthma –– Verekitug ...

In the trial, the clinical-stage company's verekitug treatment reduced the annualized asthma exacerbation rate (AAER) across all dose regimens studied in adults with severe asthma, with a 100 ...

HealthDay News — Semaglutide is associated with a significant reduction in airway exacerbations in patients with asthma or chronic obstructive pulmonary disease (COPD), according to a study presented ...

An injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, reducing the need for further treatment by 30%. The findings, published in The ...

Benralizumab can be used for the treatment of acute eosinophilic exacerbations of asthma and chronic obstructive pulmonary disease (COPD), according to a study published online Nov. 27 in The Lancet ...

Please provide your email address to receive an email when new articles are posted on . 15.4% of the population had frequent exacerbations. Greater frequency was associated with higher corticosteroid ...

Caption: Airway remodeling in asthma refers to the structural changes that happen in airway passage to the lungs, increased muscle mass and gland enlargement. Scientists from the University of Sharjah ...

A new asthma treatment, depemokimab, has shown promise in reducing exacerbations while maintaining a strong safety profile, according to findings presented at the 2025 American Academy of Allergy, ...

A study of nearly 100,000 adults found that 4.1% progressed to severe asthma within five years, while certain high-risk ...

Severe exacerbation occurred in 5.1% of patients taking albuterol/budesonide compared with 9.1% of patients taking albuterol alone in the on-treatment efficacy population. Albuterol/budesonide ...

Only 15% of patients were adherent to ICS therapy 3 months after their asthma exacerbation, and less that one-fourth of those remained adherent 9 months later. Improved adherence to inhaled ...